Dr. Di Chen joined Labcorp Central Laboratory Services’ anatomic pathology team in 2020, bringing comprehensive knowledge in the fields of molecular pathology, genomics, biochemistry and oncology. He serves as a scientist within the anatomic pathology and histology (APH) group at Labcorp’s central lab, where he is responsible for developing and validating APH-related assays for use in clinical trials. Di has also supported multiple companion diagnostic studies as a principal investigator involved in client interactions, troubleshooting and advocating for Labcorp’s anatomic pathology services.
Di earned his PhD in medical systems biology at the Institutes of Biomedical Sciences of Fudan University where he studied human hepatocellular carcinoma pathogenesis in mouse models and mechanisms involving non-coding RNA to regulate cancer development. Prior to joining Labcorp, Di participated in clinical research for the treatment of Chinese adenoid cystic carcinoma patients with immune checkpoint inhibitors in cooperation with a local hospital. His work is published in several peer-reviewed journal articles, for which he served as the first author or co-corresponding author.